Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential seasonal influenza vaccination in COPD
ACTRN12620000954921Phase 4Completed
- Sponsor
- Princess Alexandra Hospital
- Start
- Apr 2018
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ARCT-2138 in influenza, sponsored by Princess Alexandra Hospital. Primary endpoints: Change in influenza antibody response after sequential vaccination at Day 84, Seroconversion rate at Day 84 and 1 more. Started Apr 2018; status: completed.
02
Drugs
ARCT-2138
03
Conditions
influenza
Beyond the preview
Go deeper on ACTRN12620000954921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000954921.